Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 21;22(1):246.
doi: 10.1186/s12905-022-01814-x.

"It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda

Yussif Alhassan  1 , Adelline Twimukye  2 , Thokozile Malaba  3 , Landon Myer  3 , Catriona Waitt  2   4 , Mohammed Lamorde  2 , Angela Colbers  5 , Helen Reynolds  4 , Saye Khoo  4   6 , Miriam Taegtmeyer  7   6
Affiliations

"It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda

Yussif Alhassan et al. BMC Womens Health. .

Abstract

Background: Dolutegravir (DTG)-based regimens have been recommended by the WHO as the preferred first-line and second-line HIV treatment in all populations. Evidence suggests an association with weight gain, particularly among black women. Our study investigated perceptions of weight gain from DTG-based regimen use on body image and adherence of antiretroviral therapy in women living with HIV (WLHIV) in Uganda.

Methods: Between April and June 2021, we conducted semi-structured interviews involving 25 WLHIV (adolescents, women of reproductive potential and post-menopausal women) and 19 healthcare professionals (clinicians, nurses, ART managers and counsellors) purposively selected from HIV clinics in Kampala. The interviews explored perceptions of body weight and image; experiences and management of weight related side effects associated with DTG; and knowledge and communication of DTG-related risks. Data was analysed thematically in NVivo 12 software.

Results: Our findings indicate WLHIV in Uganda commonly disliked thin body size and aspired to gain moderate to high level body weight to improve their body image, social standing and hide their sero-positive status. Both WLHIV and healthcare professionals widely associated weight gain with DTG use, although it was rarely perceived as an adverse event and was unlikely to be reported or to alter medication adherence. Clinical management and pharmacovigilance of DTG-related weight gain were hampered by the limited knowledge of WLHIV of the health risks of being over-weight and obesity; lack of diagnostic equipment and resources; and limited clinical guidance for managing weight gain and associated cardiovascular and metabolic comorbidities.

Conclusions: The study highlights the significance of large body-size in promoting psychosocial wellbeing in WLHIV in Uganda. Although weight gain is recognized as a side effect of DTG, it may be welcomed by some WLHIV. Healthcare professionals should actively talk about and monitor for weight gain and occurrence of associated comorbidities to facilitate timely interventions. Improved supply of diagnostic equipment and support with sufficient guidance for managing weight gain for healthcare professionals in Uganda are recommended.

Keywords: Body image; Dolutegravir; HIV; Uganda; Weight gain; Women.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. World Health Organization, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection: recommendation for a public health approach. The World Health Organisation; 2016. - PubMed
    1. World Health Organization, Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of hiv: Interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretrovirals. The World Health Organisation; 2018.
    1. Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: Risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389. doi: 10.1093/cid/ciz999. - DOI - PMC - PubMed
    1. Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among us patients with prevalent hiv infection - a trend analysis. J Infect Dis. 2017;216(12):1525–1533. - PubMed
    1. NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of hiv-1. New England Journal of Medicine. 2019;381:816–26. - PubMed

Publication types